Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,298 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A retrospective analysis of immunohistochemically determined IRF4 (interferon regulating factor 4) expression in a consecutive cohort of 114 ovarian cancer patients.
Heimes AS, Schmidt M, Jäkel J, Almstedt K, Gebhard S, Weyer-Eiberich V, Elger T, Krajnak S, Brenner W, Hasenburg A, Battista MJ. Heimes AS, et al. Among authors: schmidt m. Arch Gynecol Obstet. 2019 Jan;299(1):239-246. doi: 10.1007/s00404-018-4941-z. Epub 2018 Oct 24. Arch Gynecol Obstet. 2019. PMID: 30357498
Atezolizumab for the treatment of triple-negative breast cancer.
Heimes AS, Schmidt M. Heimes AS, et al. Among authors: schmidt m. Expert Opin Investig Drugs. 2019 Jan;28(1):1-5. doi: 10.1080/13543784.2019.1552255. Epub 2018 Dec 1. Expert Opin Investig Drugs. 2019. PMID: 30474425 Review.
Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer.
Almstedt K, Heimes AS, Kappenberg F, Battista MJ, Lehr HA, Krajnak S, Lebrecht A, Gehrmann M, Stewen K, Brenner W, Weikel W, Rahnenführer J, Hengstler JG, Hasenburg A, Schmidt M. Almstedt K, et al. Among authors: schmidt m. Eur J Cancer. 2022 Sep;173:10-19. doi: 10.1016/j.ejca.2022.06.012. Epub 2022 Jul 12. Eur J Cancer. 2022. PMID: 35839597
Prognostic Impact of LAG-3 mRNA Expression in Early Breast Cancer.
Heimes AS, Almstedt K, Krajnak S, Runkel A, Droste A, Schwab R, Stewen K, Lebrecht A, Battista MJ, Brenner W, Hasenburg A, Gehrmann M, Hengstler JG, Schmidt M. Heimes AS, et al. Among authors: schmidt m. Biomedicines. 2022 Oct 21;10(10):2656. doi: 10.3390/biomedicines10102656. Biomedicines. 2022. PMID: 36289918 Free PMC article.
Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population.
Schmidt M, Weyer-Elberich V, Hengstler JG, Heimes AS, Almstedt K, Gerhold-Ay A, Lebrecht A, Battista MJ, Hasenburg A, Sahin U, Kalogeras KT, Kellokumpu-Lehtinen PL, Fountzilas G, Wirtz RM, Joensuu H. Schmidt M, et al. Breast Cancer Res. 2018 Feb 26;20(1):15. doi: 10.1186/s13058-018-0942-x. Breast Cancer Res. 2018. PMID: 29482642 Free PMC article. Clinical Trial.
10,298 results
You have reached the last available page of results. Please see the User Guide for more information.